APA (7th ed.) Citation

Lemech, C., Luke, J., Falchook, G., Mckean, M., Kichenadasse, G., Teng, C., . . . Puzanov, I. (2024). 678TiP A phase I, first-in-human, dose escalation and expansion study of oral pan-RAF/MEK molecular glue NST-628 in subjects with solid tumors harboring RAS-MAPK pathway alterations. Annals of Oncology, 35, S528. https://doi.org/10.1016/j.annonc.2024.08.744

Chicago Style (17th ed.) Citation

Lemech, C., et al. "678TiP A Phase I, First-in-human, Dose Escalation and Expansion Study of Oral Pan-RAF/MEK Molecular Glue NST-628 in Subjects with Solid Tumors Harboring RAS-MAPK Pathway Alterations." Annals of Oncology 35 (2024): S528. https://doi.org/10.1016/j.annonc.2024.08.744.

MLA (9th ed.) Citation

Lemech, C., et al. "678TiP A Phase I, First-in-human, Dose Escalation and Expansion Study of Oral Pan-RAF/MEK Molecular Glue NST-628 in Subjects with Solid Tumors Harboring RAS-MAPK Pathway Alterations." Annals of Oncology, vol. 35, 2024, p. S528, https://doi.org/10.1016/j.annonc.2024.08.744.